Epstein Secrets

euticals. Inc., Ophthotech Corp. Portola Pharmaceuticals Inc, Relypsa. Inc.. Synageva Biopharma Corp. Theravance Inc, Ultragenyx Pharmaceutical Inc, Versartis, Inc.. In the next 3 months. Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Akebia Therapeu

Portola Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc., Relypsa, Inc.. Synageva Biopharma Corp, Theravance Inc, Ultragenyx Pharmaceutical Inc, Versartis, Inc., Vertex Pharmaceuticals. XenoPort Inc. Within the last 12 months. Morgan Stanley has received compensation for products and services other than inve

euticals. Inc., Ophthotech Corp, Portola Pharmaceuticals Inc, Relypsa. Inc.. Synageva Biopharma Corp. Theravance Inc, Ultragenyx Pharmaceutical Inc, Versartis, Inc.. In the next 3 months. Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Akebia Therapeu

Portola Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc.. Relypsa, Inc., Synageva Biopharma Corp, Theravance Inc. Ultragenyx Pharmaceutical Inc, Versartis, Inc., Vertex Pharmaceuticals. XenoPort Inc. Within the last 12 months. Morgan Stanley has either provided or is providing non-investment banking. securi

ma (NLV-II, NASDAQ: ARRY, oncology, exited at 2.25x), Chimerix (NLV-IL, private initially, now public on NASDAQ: CMRX, novel anti-viral therapy), and Versartis (NLV-II, private, novel, long-acting human growth hormone). e Novel product platforms that offer the potential to target known, and well understood

2012 4.6 0.0 5.6 5.7 - 1.25 22.6% Treato Pharma Convergence 2013 3.0 - 3.0 3.0 - 1.00 0.0% Truveris, Inc. Convergence 2012 6.5 - 6.5 6.5 - 1.00 0.0% Versartis, Inc. Therapeutics 2011 21.2 - 93.6 93.6 - 4.41 129.4% Public Investments Therapeutics 2011 20.6 13.1 29.5 42.6 - 2.07 42.5% Total Unrealized Investments $